Initially he was thought to be mentally retarded, which was based on developmental testing and a pneumoencephalogram at 10 months which was suggestive of cerebral atrophy. He walked independently at 2 years. He spent his first 1 to 2 years in an institution for the mentally retarded but was then placed in a foster home. At school age it was evident that he was not retarded and he returned to live with his parents. At the age of 7 he had one grand mal seizure but has had none since. A brain scan at that time was normal. Vertebral radiographs disclosed fusion at C2-3. He completed grade XII in a regular high school programme, did two years of college, and is presently in an electronics technology programme. He is a bright, alert, apparently happy, well adjusted man despite his early institutional and foster home experiences including many admissions to hospital.
His general health is good. Examination disclosed the following: height 156 5 cm (height age 13), head circumference 52 8 cm (< 2 centile), arm span 150 cm, markedly overweight, left esotropia, normal visual acuity, bilateral ptosis left more than right, flat midface, prominent nose, and normal ears. His skull is markedly brachycephalic (figure) and he has a high V shaped palate with single uvula and mobile soft palate. which was treated surgically. CF was confirmed by positive pilocarpine iontophoresis sweat test at 10 days. Conventional treatment for CF was given. The clinical course of the lung disease was mild. At the age of 5 years a nasal polypectomy was performed. Liver function tests altered from this age onwards. Hepatomegaly was observed two years later. He was admitted to hospital at the age of 111 years for intravenous antibiotic treatment because of pulmonary infection. Pseudomonas aeruginosa was isolated from sputum cultures soon after this, but not repeatedly. At 131 years he was asymptomatic with discrete clubbing, hepatomegaly of 4 cm, and pubertal state AlPIG2. Weight and height were between the 10th and 25th centiles. Respiratory function tests for FVC, FEV,, and PEFR were 89%, 83%, and 76% of predicted, respectively.
Schwachman score was good (80/100) as was the Chrispin-Norman score at 6/38.
ALT (71 IU/l, normal <29 IU/l) and yGT (106 IU/l, normal < 40 IU/l) values were raised. Ultrasonographic investigations showed marked liver and pancreatic steatocirrhosis.
In conclusion, we present a patient homozygous for a frameshift mutation in the R domain of the CFTR. He has severe pancreatic and hepatic symptoms, but lung disease is mild. The 2184delA mutation predicts a stop codon 38 amino acids further in the same exon of the CFTR, but it is not known whether this mutation results in the total absence of the CFTR or in a partially functional protein. Study of the CFTR protein in different tissues will be necessary to resolve this. At the moment, the question remains whether these studies will clarify the difference in disease expression in tissues. of the CFTR. frameshift mutation in the regulatory domain in a cystic fibrosis patient homozygous for a Mild pulmonary, but severe hepatic disease
